- Home
- GNPX vs PAVM Comparison
GNPX vs PAVM Comparison
Compare GNPX & PAVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- PAVM
- Stock Information
- Founded
- GNPX 2009
- PAVM 2014
- Country
- GNPX United States
- PAVM United States
- Employees
- GNPX N/A
- PAVM N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- PAVM Medical/Dental Instruments
- Sector
- GNPX Health Care
- PAVM Health Care
- Exchange
- GNPX Nasdaq
- PAVM Nasdaq
- Market Cap
- GNPX 10.8M
- PAVM 9.4M
- IPO Year
- GNPX 2018
- PAVM 2016
- Fundamental
- Price
- GNPX $5.85
- PAVM $0.35
- Analyst Decision
- GNPX
- PAVM Strong Buy
- Analyst Count
- GNPX 0
- PAVM 1
- Target Price
- GNPX N/A
- PAVM $20.00
- AVG Volume (30 Days)
- GNPX 1.8M
- PAVM 764.8K
- Earning Date
- GNPX 11-14-2025
- PAVM 11-13-2025
- Dividend Yield
- GNPX N/A
- PAVM N/A
- EPS Growth
- GNPX N/A
- PAVM N/A
- EPS
- GNPX N/A
- PAVM 0.83
- Revenue
- GNPX N/A
- PAVM $1,020,000.00
- Revenue This Year
- GNPX N/A
- PAVM N/A
- Revenue Next Year
- GNPX N/A
- PAVM $234.47
- P/E Ratio
- GNPX N/A
- PAVM $0.42
- Revenue Growth
- GNPX N/A
- PAVM N/A
- 52 Week Low
- GNPX $4.60
- PAVM $0.30
- 52 Week High
- GNPX $117.50
- PAVM $1.25
- Technical
- Relative Strength Index (RSI)
- GNPX 57.62
- PAVM 31.78
- Support Level
- GNPX $7.71
- PAVM $0.40
- Resistance Level
- GNPX $9.89
- PAVM $0.45
- Average True Range (ATR)
- GNPX 1.35
- PAVM 0.04
- MACD
- GNPX -0.24
- PAVM -0.01
- Stochastic Oscillator
- GNPX 43.95
- PAVM 1.28
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.